title: CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
abstract: Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.
authors: Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA.
authors: Margaret K
authors: MK
authors: Callahan
authors: Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA.
authors: Michael A
authors: MA
authors: Postow
authors: Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA ; Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center , New York, NY , USA.
authors: Jedd D
authors: JD
authors: Wolchok
keywords: CLTA-4; PD-1; immunotherapy; ipilimumab; nivolumab
references: N Engl J Med. 2012 Jun 28;366(26):2455-65
references: 22658128
references: J Clin Oncol. 2013 Dec 1;31(34):4311-8
references: 24145345
references: Lancet. 2014 Sep 20;384(9948):1109-17
references: 25034862
references: J Leukoc Biol. 2013 Jul;94(1):41-53
references: 23667165
references: Immunity. 1994 Sep;1(6):501-8
references: 7534617
references: J Leukoc Biol. 2013 Jul;94(1):25-39
references: 23625198
references: N Engl J Med. 2013 Jul 11;369(2):122-33
references: 23724867
references: N Engl J Med. 2011 Jun 30;364(26):2517-26
references: 21639810
references: J Clin Oncol. 2017 Dec 1;35(34):3851-3858
references: 28678668
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Annu Rev Immunol. 2008;26:677-704
references: 18173375
references: N Engl J Med. 2015 Jan 22;372(4):320-30
references: 25399552
references: Immunity. 1994 Aug;1(5):405-13
references: 7882171
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
references: 20160101
references: J Exp Med. 1995 Aug 1;182(2):459-65
references: 7543139
references: J Clin Oncol. 2015 May 1;33(13):1430-7
references: 25452452
references: Cancer Immun. 2013;13:5
references: 23390376
references: N Engl J Med. 2013 Jul 11;369(2):134-44
references: 23724846
references: J Clin Oncol. 2010 Jul 1;28(19):3167-75
references: 20516446
references: Science. 1996 Mar 22;271(5256):1734-6
references: 8596936